Brief: Jazz Pharmaceuticals Enters Agreement With Redx Pharma To Acquire Global Rights To Kras Inhibitor Program

Redx Pharma

07/02/2024 07:03

Feb 7 (Reuters) - Jazz Pharmaceuticals Plc  JAZZ.O :
    * JAZZ PHARMACEUTICALS ENTERS DEFINITIVE AGREEMENT WITH REDX
PHARMA TO ACQUIRE GLOBAL RIGHTS TO KRAS INHIBITOR PROGRAM
    * REDX TO RECEIVE $10 MILLION UPFRONT; POTENTIAL FOR UP TO
$870
MILLION IN DEVELOPMENT, REGULATORY AND SALES MILESTONE PAYMENTS
    * REDX TO RECEIVE $10 MILLION UPFRONT; POTENTIAL FOR UP TO
$870
MILLION IN DEVELOPMENT, REGULATORY AND SALES MILESTONE PAYMENTS
    * REDX IS ALSO ELIGIBLE FOR TIERED, MID-SINGLE DIGIT
PERCENTAGE
ROYALTIES BASED ON ANY FUTURE NET SALES
    * JAZZ PHARMACEUTICALS - AS PART OF A SEPARATE COLLABORATION
AGREEMENT, JAZZ WILL PAY REDX TO PERFORM RESEARCH AND
PRECLINICAL DEVELOPMENT ACTIVITIES
    * UPFRONT MILESTONE PAYMENT FROM AGREEMENT WILL EXTEND REDX
CURRENT CASH RUNWAY INTO 2025

Source text for Eikon:  ID:nPn2C7WHja 
Further company coverage:  JAZZ.O 

 ((Reuters.Briefs@thomsonreuters.com;))